ROSEVILLE, Minn., Oct. 18 /PRNewswire/ -- Parker Hughes scientists have developed a new technology capable of preventing the development of breast cancer in mice. The results from these research studies will be published in two back-to-back papers in the November issue of the prestigious international medical journal Arzneimittelforschung (Drug Research). The technology was developed through the combined use of chemistry, biology, bioinformatics, pharmacology, and mathematics.
In the studies Parker Hughes scientists found that a novel cytotoxic nucleoside analog, Compound 003 [3'-Azidothymidine 5' - [p-Methoxyphenyl methoxyalaninyl phospate], was well tolerated in both mice and rats without toxicity. Most notably Compound 003 prolonged cancer-free survival in transgenic mice, which otherwise invariably develop HER2 positive metastatic breast cancer, without any significant side effects and at dose levels much lower than those found to be safe in animals.
An estimated 216,000 women will be diagnosed with breast cancer this year. Sadly, roughly 40,000 women will die. Women with HER2 positive breast cancer have a greater risk for recurrence of their breast cancer and an increased risk of mortality.
Uckun FM, Vassilev AO, Dibirdik I, Liu XP, Erbeck D, Tibbles HE, Qazi S, Venkatachalam TK. Anti-Cancer Activity Profile of 3'-Azidothymidine 5'-[p- Methoxyphenyl methoxyalaninyl phosphate] (Compound 003), a Novel Nucleoside Analog. Arzneimittelforschung/Drug Research, Accepted, Exp Pub 11/ 2004
Uckun FM, Chen CL, Liu XP, Dibirdik I, Venkatachalam T. In Vitro and In Vivo Pharmacokinetic Features and Metabolism of the Novel Cytotoxic Nucleoside Analog Compound 003, 3'-Azidothymidine 5'-[p-Methoxyphenyl methoxyalaninyl phosphate]. Arzneimittelforschung/Drug Research, Accepted, Exp Pub 11/2004